


## 2022 eCQM Flow – CMS104v10: Discharged on Antithrombotic Therapy (STK-02)\*

\*This flow diagram represents an overview of population criteria requirements. Please refer to the eCQM measure specification for a complete list of definitions, direct reference codes, data or timing elements included in this measure and required for submission.


### Measure Flow Diagram



## 2022 eCQM Flow – CMS104v10: Discharged on Antithrombotic Therapy (STK-02)\*

\*This flow diagram represents an overview of population criteria requirements. Please refer to the eCQM measure specification for a complete list of definitions, direct reference codes, data or timing elements included in this measure and required for submission.

### Measure Flow Diagram (Continued)



## 2022 eCQM Flow – CMS104v10: Discharged on Antithrombotic Therapy (STK-02)\*

*\*This flow diagram represents an overview of population criteria requirements. Please refer to the eCQM measure specification for a complete list of definitions, direct reference codes, data or timing elements included in this measure and required for submission.*

### Measure Flow Narrative

The measure flow diagram on the preceding pages illustrates the steps to determine the population criteria for this measure.

|                        |  |
|------------------------|--|
| Measure Description    | This measure assesses ischemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge   |
| Initial Population     | Start by identifying the initial population criteria as inpatient hospitalizations with all of the following: <ul style="list-style-type: none"><li>• patients age 18 and older</li><li>• discharged from inpatient care (non-elective admissions)</li><li>• a principal diagnosis of ischemic or hemorrhagic stroke</li><li>• a length of stay less than or equal to 120 days that ends during the measurement period</li></ul>   |
| Denominator            | The denominator criteria further constrains the initial population by inpatient hospitalizations for patients with a principal diagnosis of ischemic stroke  |
| Denominator Exclusions | The denominator exclusions criteria are used to identify a subset of the denominator population by excluding inpatient hospitalizations for patients with any of the following: <ul style="list-style-type: none"><li>• admitted for elective carotid intervention (implicit by inclusion of only non-elective hospitalizations)</li><li>• or a documented discharge disposition of:<ul style="list-style-type: none"><li>• discharged to another hospital; or</li><li>• left against medical advice; or</li><li>• expired; or</li><li>• discharged to either a health care facility or home, for hospice care</li></ul></li><li>• or have comfort measures documented</li></ul> |

## 2022 eCQM Flow – CMS104v10: Discharged on Antithrombotic Therapy (STK-02)\*

*\*This flow diagram represents an overview of population criteria requirements. Please refer to the eCQM measure specification for a complete list of definitions, direct reference codes, data or timing elements included in this measure and required for submission.*

### Measure Flow Narrative (Continued)

The measure flow diagram on the preceding pages illustrates the steps to determine the population criteria for this measure.

|                        |   |
|------------------------|---|
| Numerator              | The numerator criteria identify a subset of the denominator population (that did not meet the denominator exclusions criteria) by including inpatient hospitalizations for patients prescribed or continuing to take antithrombotic therapy at hospital discharge   |
| Denominator Exceptions | <p>The denominator exceptions criteria identify a subset of the denominator population (that did not meet the denominator exclusions criteria or numerator criteria) by excluding inpatient hospitalizations for patients who have either:</p> <ul style="list-style-type: none"><li>• a documented reason for not prescribing antithrombotic therapy at discharge (either a qualifying medical or patient refusal)</li><li>• or received pharmacological contraindications for antithrombotic therapy, Ticagrelor or Prasugrel, at discharge</li></ul> |